USPSTF recommends men older than 35 and women older than 45 to be screened. NCE-ATP III recommends all adults older than 20 to be screened as it may lead potential lifestyle modification that can reduce risks of other diseases. However, screening should be done for those with known CHD or risk-equivalent conditions (e.g. Acute Coronary Syndrome, history of heart attacks, Stable or Unstable angina, Transient ischemic attacks, Peripheral arterial disease of atherosclerotic origins, coronary or other arterial revascularization). Screening frequency
Adults 20 years and older should have the cholesterol checked every four to six years, and most screening guidelines recommends testing every 5 years. USPSTF recommends increased frequency for people with elevated risk of CHD, which may be determined using cardiovascular disease risk scores. Management
Management of hyperlipidemia includes maintenance of a normal body weight, increased physical activity, and decreased consumption of refined carbohydrates and simple sugars. Prescription drugs may be used to treat some people having significant risk factors, such as cardiovascular disease, LDL cholesterol greater than 190 mg/dL or diabetes. Common medication therapy is a statin. HMG-CoA reductase inhibitors
Competitive inhibitors of HMG-CoA reductase, such as lovastatin, atorvastatin, fluvastatin, pravastatin, simvastatin, rosuvastatin, and pitavastatin, inhibit the synthesis of mevalonate, a precursor molecule to cholesterol. This medication class is especially effective at decreasing elevated LDL cholesterol. Major side effects include elevated transaminases and myopathy. Fibric acid derivatives
Fibric acid derivatives, such as gemfibrozil and fenofibrate, function by increasing the lipolysis in adipose tissue via activation of peroxisome proliferator-activated receptor-α.
Doctors have found that antidepressant (PDE-5 inhibitors) medicines have shown positive results in controlling the Dhat syndromes psychological causes." Epidemiology
Dhat syndrome has been reported throughout South Asia in several communities." History
The term Dhat gets its origin from the Sanskrit word Dhatu (धातु), which, according to the Sushruta Samhita, means "elixir that constitutes the body". Indian doctor Narendra Wig coined the term Dhat syndrome in 1960 and described it as being characterized by vague psychosomatic symptoms of fatigue, weakness, anxiety, loss of appetite, guilt, and sexual dysfunction, attributed by the patient to loss of semen in nocturnal emission, through urine or masturbation. Literature describing semen as a vital constituent of the human body dates back to 1500 BC. The disorders of Dhatus have been elucidated in the Charaka Samhita, which describes a disorder called Shukrameha (शुक्रमेह) in which there is a passage of semen in the urine. In China, various names such as (Shen Kuei), Sri Lanka (Prameha) and other parts of South East Asia (Jiryan) symptoms and conditions are similar to dhatus. The International Classification of diseases ICD-10 classifies Dhat syndrome as both a neurotic disorder (code F48.8) and a culture-specific disorder (Annexe 2) caused by "undue concern about the debilitating effects of the passage of semen". Society and culture
Some doctors believe Dhat syndrome to be either a culture-bound presentation of clinical depression, as a somatized set of symptoms, or a result of Western doctors misinterpretation of patients descriptions of their condition.Dhat syndrome is very common in Nepali culture as well.